Critics say newly appointed FDA Chairman Andrew von Eschenbach needs to choose between his job as head of the National Cancer Institute and his new role at the Food and Drug Administration. Some argue there is an inherent conflict between the National Cancer Institute's mission, which is generally seen to be focused on developing new medicines and treatments as quickly as possible, and the FDA's role as regulatory watchdog. Supporters counter that a no-nonsense approach toward approvals is exactly what makes von Eschenbach an excellent choice.

- see this story from the AP

PLUS: More details emerged about Lester Crawford's sudden departure last week. A family relative has confirmed that the former chairman's decision to step down was related to a failure to report a financial interest. Not everybody is buying the story. Article